PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsHyoscyamine
Hyoscyamine
Hyoscyamine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
musculoskeletal diseasesD009140
digestive system diseasesD004066
stomatognathic diseasesD009057
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
nervous system diseasesD009422
urogenital diseasesD000091642
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
Show 1 more
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
anaspazunapproved drug other2024-07-25
atropineANDA2024-10-16
atropine careunapproved drug other2011-01-06
atropine sulfateANDA2025-06-16
diphenoxylate hcl and atropine sulfateANDA2010-03-24
diphenoxylate hydrochloride and atropine sulfateANDA2025-06-12
direct rxNDA authorized generic2015-08-05
donnatalunapproved drug other2024-12-05
donnatal extentabsunapproved drug other2011-10-17
gabapentinANDA2017-05-11
Show 40 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A03: Drugs for functional gastrointestinal disorders
— A03B: Belladonna and derivatives containing drugs, plain for functional gastrointestinal disorders
— A03BA: Belladonna alkaloids, tertiary amines for functional gastrointestinal disorders
— A03BA03: Hyoscyamine
— A03C: Antispasmodics in combination with psycholeptics
— A03CB: Belladonna and derivatives in combination with psycholeptics
— A03CB31: Hyoscyamine and psycholeptics
HCPCS
Code
Description
J1980
Injection, hyoscyamine sulfate, up to 0.25 mg
Clinical
Clinical Trials
372 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MyopiaD009216EFO_0003927H52.1111317102873
Neuromuscular blockadeD019148——13312523
AnesthesiaD000758————32813
HypotensionD007022EFO_0005251I951——2811
PoisoningD011041EFO_0008546T65.912222411
Postoperative painD010149—G89.18———3710
VomitingD014839—R11.1——13610
BradycardiaD001919—R00.1—1—5410
NauseaD009325—R11.0——1359
Postoperative nausea and vomitingD020250EFO_0004888———1269
Show 76 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Degenerative myopiaD047728—H44.2234—512
General anesthesiaD000768———22—37
Emergence deliriumD000071257———11—34
DeliriumD003693—R41.0—11—23
LymphomaD008223—C85.9211——3
UveitisD014605EFO_1001231H20.9——1—12
PremedicationD011292———22——2
Replacement arthroplasty hipD019644————1—12
Chest painD002637—R07.9——1—12
AnisometropiaD015858—H52.31——1—12
Show 20 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50—2——24
NeoplasmsD009369—C8022———3
Lung neoplasmsD008175—C34.9021———2
Non-small-cell lung carcinomaD002289——22———2
Brain neoplasmsD001932EFO_0003833C71—1——12
Colonic neoplasmsD003110—C1812———2
RhinitisD012220EFO_0008521J3111———2
Allergic rhinitis seasonalD006255EFO_0003956J3011———2
Heart arrestD006323EFO_0009492I46—1——12
SarcomaD012509———1———1
Show 21 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1———23
Prediabetic stateD011236EFO_1001121R73.031———12
Glucose intoleranceD018149HP_0000833R73.031———12
HypoglycemiaD007003—E16.22————2
SialorrheaD012798—K11.71———12
Orthostatic intoleranceD054971——1———12
DeathD003643PATO_0001422—1———12
Digestive system physiological phenomenaD004068——1————1
Gastrointestinal motilityD005769——1————1
LeukemiaD007938—C951————1
Show 16 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cystic fibrosisD003550EFO_0000390E84————44
Coronary artery diseaseD003324—I25.1————33
AnalgesiaD000698——————33
GlaucomaD005901EFO_0000516H40————22
Conduction anesthesiaD000765——————22
Renal insufficiencyD051437—N19————22
Psychomotor agitationD011595——————22
HerniaD006547—K40-K46————22
Depressive disorderD003866EFO_1002014F32.A————22
Intravenous anesthesiaD000771——————22
Show 85 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameHyoscyamine
INN—
Description
(S)-atropine is an atropine with a 2S-configuration. It is functionally related to a (S)-tropic acid. It is a conjugate base of a (S)-atropinium.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)[C@H](CO)c1ccccc1)C2
Identifiers
PDB—
CAS-ID101-31-5
RxCUI—
ChEMBL IDCHEMBL1331216
ChEBI ID17486
PubChem CID154417
DrugBankDB00424
UNII ID—
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Hyoscyamine
+
Phenazopyridine
+
Butabarbital
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Hyoscyamine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
7,303 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use